Corline Biomedical: Our view on the phase I data
Research Note
2020-06-10
17:15
Redeye reiterate its positive stance towards Corline following the release of Phase I data with its lead candidate Renaparin. As stated in our initiation report, we saw good prospects of a positive outcome and assigned the trial a probability of success of 85%. With today’s encouraging safety data, we now consider the asset Phase II-ready and raise of our Base case to SEK 35 (30).
LS
Ludvig Svensson
Disclosures and disclaimers